Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Diseases cardiovascular

The NOS inhibitor L-iV -nitroarginine is protective against IR injury, having [Pg.30]


Unfortunately, excess consumption of fatty foods has been correlated with serious human disease conditions. Effects on cardiovascular disease (95), cancer (96), and function of the immune system (97) have been shown. Numerous studies have been conducted to determine the effects of saturated, monounsaturated, and polyunsaturated fatty acids on semm cholesterol and more recently high density Hpoprotein (HDL) and low density Hpoprotein... [Pg.134]

Other cardiovascular diseases cover a long Hst of circulatory problems, including heart faHure, peripheral vascular disease, cardiomyopathy, and arrhythmias. [Pg.177]

Anxiety disorders and insomnia represent relatively common medical problems within the general population. These problems typically recur over a person s lifetime (3,4). Epidemiological studies in the United States indicate that the lifetime prevalence for significant anxiety disorders is about 15%. Anxiety disorders are serious medical problems affecting not only quaUty of life, but additionally may indirecdy result in considerable morbidity owing to association with depression, cardiovascular disease, suicidal behavior, and substance-related disorders. [Pg.217]

W. B. Kaimel and T. R. Dauber, Hypertensive Cardiovascular Disease The Framingham Study. Hypertension Mechanisms and Management, Framingham, Mass., 1973. [Pg.186]

Vitamin E can also act as an antioxidant (qv) in animals and humans alone or in combination with vitamin C (qv). Both are good free-radical scavengers with the vitamin C acting to preserve the levels of vitamin E (35). Vitamin E in turn can preserve the levels of vitamin A in animals (13). It has been shown that vitamin E reduces the incidence of cardiovascular disease (36—39). This most likely results from the antioxidant property of the vitamin which inhibits the oxidation of low density Hpoproteins (LDLs) (40—42). The formation of the oxidized LDLs is considered important in decreasing the incidence of cardiovascular disease (43). [Pg.147]

Lime and Lime-Soda Processes. The first softening plant in the early 1900s used the lime softening process with fill and draw units. Later, continuous-treatment units, which greatiy increased the amount of water that could be treated in a faciUty of given size, were developed. More than 1000 municipahties soften water. Most are in the Midwest and in Florida. However, concern for the adverse effect of soft water on cardiovascular disease (CVD) may limit the number of plants that introduce softening. [Pg.278]

Other Cardiovascular Agents Effecting Atherosclerosis. A large amount of clinical data is available concerning semm Upid profiles in patients subjected to dmg therapy for other cardiovascular diseases. Atheroma, for example, may be the underlying cause of hypertension and myocardial infarction. There are on the order of 1.5 million heart attacks pet year in the United States (155). [Pg.131]

Hypertension is one of the two principal risk factors of many cardiovascular diseases, such as coronary heart disease (CHD), stroke, and CHF. Individuals are considered hypertensive if their systoHc arterial blood pressure is over 140 mm Hg (18.7 Pa) or their diastoHc arterial blood pressure is over 90 mm Hg (12 Pa). Over 60 million people, or one-third of the adult population in the United States are estimated to be hypertensive (163). About 90% of these patients are classified as primary or essential hypertensive because the etiology of their hypertension is unknown. It is generally agreed that there is a very strong genetic or hereditary component to this disease. [Pg.132]

One study (83) indicated that in mildly hypertensive male patients treated with an antihypertensive dmg, those below the age of 50 or having no clinical evidence of cardiovascular disease had no significant improvement from cardiovascular diseases within 3.3 years those over the age of 50 or having pre-existing cardiovascular disease benefited significantly. [Pg.212]

In a study with 3427 male and female patients having DBP of 95—109 mm Hg (12—15 Pa), and no clinical evidence of cardiovascular diseases, half of the patients were placebo-treated and half were SC antihypertensive dmg-treated, ie, step 1, chlorothiazide step 2, methyldopa, propranolol [525-66-6], or pindolol [13523-86-9], and step 3, hydralazine, or clonidine [4205-90-7] (86). Overall, when the DBP was reduced below 100 mm Hg (13 Pa), there were more deaths in the dmg-treated group than in the placebo group. The data suggest reduction of blood pressure by antihypertensive dmg treatment that includes a diuretic is accompanied by increased cardiovascular risks. [Pg.212]

The Oslo Trial (87) enrolled 785 male patients <50 years of age with DBP <110 mm Hg (15 Pa) and free of clinical evidence of cardiovascular disease. If the initial DBP was <100 mm Hg (13 Pa), there were no differences in mortaUty or cardiovascular events in the placebo- or dmg-treated groups. If the initial DBP was >100 mm Hg, then the incidence of cardiovascular disease was greater in the dmg-treated than in the placebo-treated group. [Pg.212]

When adrninistered long-term for the treatment of hypertension, diuretics fulfill the goals of preventing cardiovascular disease and increasing longevity. However, diuretic therapy may produce both side and toxic effects that are significant in certain patient subgroups, eg, diabetics and cardiac patients. [Pg.212]

Department of Health, Nutritional Aspects of Cardiovascular Disease, Report on Health and Soeial... [Pg.123]

Thus, it is apparent that soya, some soya products and linseed oil influence blood lipid levels, particularly cholesterol and LDL cholesterol. While the extent of the reduction appears to largely depend on an individual s initial serum cholesterol level, the maximum reductions observed are of the order of 10-15%. For hyperlipidemic individuals this may not be a marked reduction, but such an effect on the general population may well have a beneficial effect on the overall incidence of cardiovascular disease and atherosclerosis. The possibility that non-phytoestrogenic dietary components may contribute to the hypocholes-terolemic properties cannot, however, be discounted. Indeed, certain types of dietary fibre have been shown to have a hypolipidemic effect via their ability to increase faecal excretion rates. [Pg.126]

CO Reduction in the ability of the circulatory system to transport O Impairment of performance on tasks requiring vigilance Aggravation of cardiovascular disease. [Pg.108]

Aggravation of cardiovascular disease (i.e., decreased exercise capacity in patients with angina pectoris, intermittent claudication, or peripheral arteriosclerosis)... [Pg.368]


See other pages where Diseases cardiovascular is mentioned: [Pg.168]    [Pg.353]    [Pg.243]    [Pg.104]    [Pg.381]    [Pg.580]    [Pg.250]    [Pg.430]    [Pg.155]    [Pg.167]    [Pg.171]    [Pg.177]    [Pg.177]    [Pg.177]    [Pg.180]    [Pg.445]    [Pg.7]    [Pg.43]    [Pg.33]    [Pg.110]    [Pg.131]    [Pg.144]    [Pg.145]    [Pg.433]    [Pg.8]    [Pg.88]    [Pg.112]    [Pg.116]    [Pg.123]    [Pg.133]    [Pg.133]    [Pg.389]    [Pg.252]    [Pg.332]   
See also in sourсe #XX -- [ Pg.112 , Pg.123 , Pg.126 , Pg.132 ]

See also in sourсe #XX -- [ Pg.5 , Pg.6 , Pg.7 , Pg.8 , Pg.9 , Pg.10 , Pg.11 , Pg.12 , Pg.13 ]

See also in sourсe #XX -- [ Pg.90 , Pg.95 ]

See also in sourсe #XX -- [ Pg.334 ]

See also in sourсe #XX -- [ Pg.49 , Pg.62 ]

See also in sourсe #XX -- [ Pg.18 , Pg.40 , Pg.52 , Pg.74 , Pg.124 , Pg.169 , Pg.234 , Pg.255 , Pg.339 , Pg.341 ]

See also in sourсe #XX -- [ Pg.55 , Pg.56 , Pg.57 , Pg.58 , Pg.59 , Pg.60 , Pg.61 , Pg.70 , Pg.134 , Pg.135 ]

See also in sourсe #XX -- [ Pg.433 ]

See also in sourсe #XX -- [ Pg.61 , Pg.75 ]

See also in sourсe #XX -- [ Pg.130 ]

See also in sourсe #XX -- [ Pg.234 ]

See also in sourсe #XX -- [ Pg.54 ]

See also in sourсe #XX -- [ Pg.158 ]

See also in sourсe #XX -- [ Pg.16 , Pg.110 , Pg.118 , Pg.168 ]

See also in sourсe #XX -- [ Pg.200 , Pg.281 , Pg.286 ]

See also in sourсe #XX -- [ Pg.241 , Pg.242 , Pg.246 , Pg.249 , Pg.253 ]

See also in sourсe #XX -- [ Pg.249 ]

See also in sourсe #XX -- [ Pg.20 , Pg.135 , Pg.190 , Pg.195 ]

See also in sourсe #XX -- [ Pg.157 , Pg.158 , Pg.161 , Pg.172 , Pg.175 ]

See also in sourсe #XX -- [ Pg.125 , Pg.127 , Pg.225 , Pg.234 ]

See also in sourсe #XX -- [ Pg.24 , Pg.287 ]

See also in sourсe #XX -- [ Pg.150 , Pg.194 , Pg.207 , Pg.234 ]

See also in sourсe #XX -- [ Pg.99 ]

See also in sourсe #XX -- [ Pg.314 ]

See also in sourсe #XX -- [ Pg.879 ]

See also in sourсe #XX -- [ Pg.230 ]

See also in sourсe #XX -- [ Pg.230 ]

See also in sourсe #XX -- [ Pg.588 ]

See also in sourсe #XX -- [ Pg.357 ]

See also in sourсe #XX -- [ Pg.867 ]

See also in sourсe #XX -- [ Pg.10 , Pg.24 , Pg.25 , Pg.33 , Pg.34 , Pg.37 , Pg.41 , Pg.55 , Pg.58 , Pg.62 , Pg.65 , Pg.77 , Pg.87 , Pg.94 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 ]

See also in sourсe #XX -- [ Pg.5 , Pg.67 , Pg.201 , Pg.259 , Pg.260 , Pg.261 , Pg.262 , Pg.265 , Pg.266 , Pg.268 , Pg.269 , Pg.285 , Pg.339 , Pg.342 , Pg.570 ]

See also in sourсe #XX -- [ Pg.7 , Pg.8 , Pg.9 , Pg.10 , Pg.11 , Pg.12 , Pg.13 , Pg.14 , Pg.158 ]

See also in sourсe #XX -- [ Pg.40 , Pg.57 ]

See also in sourсe #XX -- [ Pg.29 , Pg.30 , Pg.34 , Pg.88 , Pg.114 ]

See also in sourсe #XX -- [ Pg.42 ]

See also in sourсe #XX -- [ Pg.8 , Pg.693 , Pg.732 , Pg.745 ]

See also in sourсe #XX -- [ Pg.271 ]

See also in sourсe #XX -- [ Pg.132 ]

See also in sourсe #XX -- [ Pg.52 , Pg.65 ]

See also in sourсe #XX -- [ Pg.77 ]

See also in sourсe #XX -- [ Pg.241 ]

See also in sourсe #XX -- [ Pg.49 , Pg.62 ]

See also in sourсe #XX -- [ Pg.205 ]

See also in sourсe #XX -- [ Pg.4 , Pg.164 , Pg.221 , Pg.226 ]

See also in sourсe #XX -- [ Pg.23 , Pg.30 , Pg.155 , Pg.524 , Pg.739 ]

See also in sourсe #XX -- [ Pg.508 ]

See also in sourсe #XX -- [ Pg.155 , Pg.524 ]

See also in sourсe #XX -- [ Pg.49 , Pg.53 , Pg.55 , Pg.75 , Pg.133 , Pg.201 ]

See also in sourсe #XX -- [ Pg.376 , Pg.380 ]

See also in sourсe #XX -- [ Pg.100 ]

See also in sourсe #XX -- [ Pg.148 , Pg.149 , Pg.150 ]

See also in sourсe #XX -- [ Pg.376 ]

See also in sourсe #XX -- [ Pg.14 , Pg.102 , Pg.122 ]

See also in sourсe #XX -- [ Pg.57 ]

See also in sourсe #XX -- [ Pg.431 , Pg.541 ]

See also in sourсe #XX -- [ Pg.5 , Pg.19 , Pg.25 , Pg.26 , Pg.27 , Pg.28 , Pg.42 , Pg.43 , Pg.44 , Pg.56 , Pg.128 , Pg.137 , Pg.158 , Pg.180 , Pg.198 , Pg.202 , Pg.219 , Pg.256 , Pg.273 , Pg.278 , Pg.288 , Pg.300 ]

See also in sourсe #XX -- [ Pg.450 , Pg.452 ]

See also in sourсe #XX -- [ Pg.40 , Pg.49 , Pg.50 , Pg.64 , Pg.77 , Pg.90 , Pg.91 , Pg.127 , Pg.176 , Pg.195 , Pg.224 , Pg.225 , Pg.308 , Pg.316 ]

See also in sourсe #XX -- [ Pg.284 ]

See also in sourсe #XX -- [ Pg.40 ]

See also in sourсe #XX -- [ Pg.2 , Pg.18 ]

See also in sourсe #XX -- [ Pg.3 , Pg.119 , Pg.152 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 , Pg.4 ]

See also in sourсe #XX -- [ Pg.44 , Pg.405 , Pg.415 , Pg.422 , Pg.423 , Pg.434 , Pg.436 , Pg.436 , Pg.442 ]

See also in sourсe #XX -- [ Pg.233 ]

See also in sourсe #XX -- [ Pg.24 , Pg.25 , Pg.38 , Pg.41 ]

See also in sourсe #XX -- [ Pg.714 , Pg.715 ]

See also in sourсe #XX -- [ Pg.27 , Pg.64 , Pg.165 , Pg.216 , Pg.220 , Pg.251 ]

See also in sourсe #XX -- [ Pg.133 ]

See also in sourсe #XX -- [ Pg.25 , Pg.35 , Pg.139 , Pg.354 , Pg.494 , Pg.497 , Pg.743 ]

See also in sourсe #XX -- [ Pg.175 , Pg.197 ]

See also in sourсe #XX -- [ Pg.32 , Pg.33 , Pg.38 ]

See also in sourсe #XX -- [ Pg.29 , Pg.51 , Pg.98 , Pg.275 ]

See also in sourсe #XX -- [ Pg.40 ]

See also in sourсe #XX -- [ Pg.717 ]

See also in sourсe #XX -- [ Pg.13 , Pg.47 , Pg.50 , Pg.58 , Pg.71 , Pg.91 , Pg.100 , Pg.106 , Pg.145 , Pg.280 , Pg.288 , Pg.290 , Pg.294 , Pg.315 , Pg.319 , Pg.329 , Pg.331 , Pg.335 , Pg.354 , Pg.357 , Pg.358 , Pg.360 , Pg.381 , Pg.397 , Pg.399 , Pg.401 , Pg.443 , Pg.458 , Pg.469 , Pg.470 , Pg.473 , Pg.482 , Pg.497 , Pg.513 , Pg.568 , Pg.582 , Pg.595 , Pg.603 , Pg.608 , Pg.609 , Pg.613 , Pg.618 , Pg.621 , Pg.622 , Pg.624 , Pg.625 , Pg.696 , Pg.697 , Pg.698 , Pg.699 ]

See also in sourсe #XX -- [ Pg.657 , Pg.658 , Pg.659 , Pg.660 , Pg.661 , Pg.662 , Pg.663 , Pg.664 , Pg.665 , Pg.666 , Pg.667 , Pg.668 , Pg.669 ]

See also in sourсe #XX -- [ Pg.84 , Pg.99 , Pg.113 , Pg.148 , Pg.190 , Pg.197 , Pg.199 , Pg.204 , Pg.206 , Pg.209 , Pg.220 , Pg.222 , Pg.242 ]

See also in sourсe #XX -- [ Pg.382 ]

See also in sourсe #XX -- [ Pg.126 , Pg.615 ]

See also in sourсe #XX -- [ Pg.86 , Pg.88 ]

See also in sourсe #XX -- [ Pg.245 ]

See also in sourсe #XX -- [ Pg.45 , Pg.93 , Pg.98 , Pg.100 , Pg.206 , Pg.208 , Pg.213 , Pg.216 ]

See also in sourсe #XX -- [ Pg.121 , Pg.181 ]

See also in sourсe #XX -- [ Pg.2 , Pg.3 , Pg.12 , Pg.14 , Pg.18 , Pg.221 , Pg.222 , Pg.225 , Pg.245 , Pg.255 , Pg.259 , Pg.286 , Pg.289 ]

See also in sourсe #XX -- [ Pg.519 ]

See also in sourсe #XX -- [ Pg.87 ]

See also in sourсe #XX -- [ Pg.175 ]

See also in sourсe #XX -- [ Pg.342 ]

See also in sourсe #XX -- [ Pg.566 , Pg.571 , Pg.589 ]

See also in sourсe #XX -- [ Pg.281 , Pg.282 ]

See also in sourсe #XX -- [ Pg.366 , Pg.398 , Pg.993 ]

See also in sourсe #XX -- [ Pg.16 ]

See also in sourсe #XX -- [ Pg.13 ]

See also in sourсe #XX -- [ Pg.577 , Pg.663 ]




SEARCH



African Americans cardiovascular disease

Animal models cardiovascular disease

Antidepressant drugs cardiovascular disease

Antioxidant properties cardiovascular disease

Atherosclerosis and cardiovascular disease

Atherosclerotic cardiovascular disease

Atropine cardiovascular disease

CVD - cardiovascular disease

Cardiac and cardiovascular diseases

Cardiovascular Disease Models

Cardiovascular disease (cont

Cardiovascular disease 3—Carotene

Cardiovascular disease Fatty acids

Cardiovascular disease Fish oils

Cardiovascular disease Garlic

Cardiovascular disease Ginkgoaceae against

Cardiovascular disease Mediterranean diet

Cardiovascular disease Polyunsaturated fatty

Cardiovascular disease Prevention Study)

Cardiovascular disease Seven Countries Study

Cardiovascular disease Thromboxane

Cardiovascular disease acids

Cardiovascular disease advantages

Cardiovascular disease and

Cardiovascular disease and diabetes

Cardiovascular disease angiotensin-converting enzyme

Cardiovascular disease antioxidant effects

Cardiovascular disease arrhythmia

Cardiovascular disease arterial blockage

Cardiovascular disease arteriosclerosis

Cardiovascular disease ascorbic acid

Cardiovascular disease blood levels

Cardiovascular disease cadmium

Cardiovascular disease captopril

Cardiovascular disease cardiac catheterization

Cardiovascular disease case-control studies

Cardiovascular disease cholesterol effects

Cardiovascular disease clinical trials role

Cardiovascular disease cobalamins

Cardiovascular disease computed tomography

Cardiovascular disease congestive heart failure

Cardiovascular disease coronary angiography

Cardiovascular disease coronary artery bypass surgery

Cardiovascular disease coronary occlusions

Cardiovascular disease deficiency effect

Cardiovascular disease definition

Cardiovascular disease described

Cardiovascular disease description

Cardiovascular disease determination

Cardiovascular disease diabetes mellitus and

Cardiovascular disease diet association

Cardiovascular disease dietary intake

Cardiovascular disease disorder

Cardiovascular disease drug therapy

Cardiovascular disease effect

Cardiovascular disease electrocardiogram

Cardiovascular disease enalapril

Cardiovascular disease endothelin antagonists

Cardiovascular disease endothelium

Cardiovascular disease epidemiology

Cardiovascular disease epilepsy

Cardiovascular disease exercise testing

Cardiovascular disease factor

Cardiovascular disease fish consumption

Cardiovascular disease folate

Cardiovascular disease folic acid deficiency

Cardiovascular disease free radical-induced

Cardiovascular disease future

Cardiovascular disease heart failure

Cardiovascular disease heart rate

Cardiovascular disease homocysteine

Cardiovascular disease hormone replacement therapy

Cardiovascular disease hypercholesterolemia

Cardiovascular disease hyperhomocysteinemia

Cardiovascular disease hypertension

Cardiovascular disease hypertension and

Cardiovascular disease in women

Cardiovascular disease incidence

Cardiovascular disease infarction

Cardiovascular disease inflammation

Cardiovascular disease inhibitors

Cardiovascular disease ligands

Cardiovascular disease limitations

Cardiovascular disease lipid metabolism

Cardiovascular disease lisinopril

Cardiovascular disease lovastatin

Cardiovascular disease lycopene

Cardiovascular disease magnetic resonance imaging

Cardiovascular disease meta-analysis studies

Cardiovascular disease mortality

Cardiovascular disease mortality risk

Cardiovascular disease myocardial infarction

Cardiovascular disease niacin

Cardiovascular disease niacin effect

Cardiovascular disease obesity

Cardiovascular disease obesity and

Cardiovascular disease overview

Cardiovascular disease patients

Cardiovascular disease patients with ESRD

Cardiovascular disease peripheral circulation

Cardiovascular disease physical examination

Cardiovascular disease phytochemicals

Cardiovascular disease potassium deficiency

Cardiovascular disease pravastatin

Cardiovascular disease preventing

Cardiovascular disease prevention

Cardiovascular disease primary

Cardiovascular disease prospective cohort studies

Cardiovascular disease pulses

Cardiovascular disease rabbit model

Cardiovascular disease ramipril

Cardiovascular disease reactive oxygen species

Cardiovascular disease renin-angiotensin system

Cardiovascular disease risk factors

Cardiovascular disease risk indicator

Cardiovascular disease risk reduction

Cardiovascular disease safety testing

Cardiovascular disease secondary intervention

Cardiovascular disease smokers

Cardiovascular disease stroke

Cardiovascular disease supplementation

Cardiovascular disease therapeutic interventions

Cardiovascular disease treatment

Cardiovascular disease uptake

Cardiovascular disease vascular effect

Cardiovascular disease, factors affecting

Cardiovascular disease, homocysteine vitamin

Cardiovascular disease, world incidence

Cardiovascular disease/defects

Cardiovascular disease/health

Cardiovascular diseases antioxidant therapy

Cardiovascular diseases atherosclerosis

Cardiovascular diseases carotenoids

Cardiovascular diseases familial hypercholesterolemia

Cardiovascular diseases flavonoids

Cardiovascular diseases herbal medicine

Cardiovascular diseases ischemia

Cardiovascular diseases lipids

Cardiovascular diseases oxidative stress

Cardiovascular diseases resveratrol inhibits

Cardiovascular diseases statins

Cardiovascular diseases sympathetic nervous system

Cardiovascular diseases therapeutic options

Cardiovascular diseases thrombosis

Cardiovascular diseases, management

Cardiovascular disorders complicating renal disease

Cardiovascular disorders ischemic heart disease

Cardiovascular system disease

Carotenoids cardiovascular disease prevention

Chronic cardiovascular disease

Cocaine cardiovascular diseases

Cohort studies cardiovascular disease

Dietary cardiovascular disease

Diseases Cardiovascular disease Complex

Diseases cardiovascular, cardiac

Ephedrine cardiovascular diseases

Erectile dysfunction cardiovascular disease

Folic acid cardiovascular disease

Fruit, folate cardiovascular disease

Functional benefits cardiovascular disease and diabetes

Functional benefits of carotenoids vision, cancer and cardiovascular disease

Gene and Cell-based Therapies for Cardiovascular Disease

Gene therapy cardiovascular diseases

Health effects cardiovascular disease

Human diseases Cardiovascular

Hyperhomocysteinemia and Cardiovascular Disease

INDEX Cardiovascular diseases

Lead cardiovascular disease

Lignans cardiovascular disease

Nitric Oxide Donors in Cardiovascular Disease

Nuclear Receptors as Targets in Cardiovascular Diseases

Nutrient-disease interactions cardiovascular diseases

Nutritional phenolics and cardiovascular disease

Obesity cardiovascular disease risk

Obesity-related chronic disease cardiovascular diseases

Observational studies cardiovascular disease

Older people cardiovascular disease

Particulate matter cardiovascular diseases

Peroxidation and Cardiovascular Disease

Phenolics cardiovascular disease

Plant-based diets and prevention of cardiovascular disease

Plasma levels, cardiovascular diseases

Polyunsaturated cardiovascular disease risk

Protection against cardiovascular disease

Randomized controlled trials cardiovascular disease

Respiratory and cardiovascular diseases

Salicylate cardiovascular disease

Sexual activity cardiovascular disease

Subject cardiovascular disease

Supplements cardiovascular disease

The health effects of phytoestrogens osteoporosis, cardiovascular disease and thyroid function

Vitamin C in Cardiovascular Disease

Vitamin E and Cardiovascular Disease

Vitamin in cardiovascular disease

Vitamins cardiovascular disease

Women cardiovascular disease

© 2019 chempedia.info